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and 3Nijmegen University Centre for Infectious Diseases, Nijmegen, The Netherlands
(See the editorial commentary by File and Gross on pages 942–4)
Background. Limited data exist on the most effective approach to increase the quality of antibiotic use for
lower respiratory tract infections at hospitals.
Methods. One thousand nine hundred six patients with community-acquired pneumonia or an exacerbation
of chronic obstructive pulmonary disease (acute exacerbation of chronic bronchitis) were included in a cluster-
randomized, controlled trial at 6 medium-to-large Dutch hospitals. A multifaceted guideline-implementation
strategy that was tailored to baseline performance and considered the barriers in the target group was used.
Principal outcome measures were (1) guideline-adherent antibiotic prescription, (2) adaptation of dose and dose
interval of antibiotics according to renal function, (3) switches in therapy, (4) streamlining of therapy, and (5)
Gram staining and culture of sputum samples. Secondary process outcomes were applicable to community-acquired
pneumonia (e.g., timely administration of antibiotics) or acute exacerbation of chronic bronchitis (e.g., not pre-
scribing macrolides).
Results. The rate of guideline-adherent antibiotic prescription increased from 50.3% to 64.3% in the inter-
vention hospitals (odds ratio [OR], 2.63; 95% confidence interval [CI], 1.57–4.42; ). The rate of adaptationPp .0008
of antibiotic dose according to renal function increased from 79.4% to 95.1% in the intervention hospitals (OR,
7.32; 95% CI, 2.09–25.7; ). The switch from intravenous to oral therapy improved more in the controlPp .02
hospitals (from 53.3% to 71.9%) than in the intervention hospitals (from 74% to 83.6%). The change from broad-
spectrum empirical therapy to pathogen-directed therapy improved by 5.7% in the intervention hospitals (P p
not significant). Fewer sputum samples were obtained from both the intervention group (rate of sputum samples
obtained decreased from 55.8% to 53.1%) and the control group (rate of sputum samples obtained decreased
from 49.6% to 42.7%). Timely administration of antibiotics for community-acquired pneumonia increased sig-
nificantly in the intervention group (from 55.2% to 62.9%; OR, 2.49; 95% CI, 1.11–5.57; ).Pp .026
Conclusions. With regard to some important aspects, tailoring interventions to change antibiotic use improved
the quality of treatment for patients hospitalized with lower respiratory tract infection.
Improvement of the quality of antibiotic use for hos-
pitalized patients with lower respiratory tract infection
(LRTI)—for example, by means of the timely admin-
istration of antibiotics and ensuring the appropriate
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selection of the initial antibiotic regimen—is related to
better patient outcomes [1, 2]. Inappropriate use of
antibiotics contributes to the emergence and spread of
drug-resistant microorganisms, as well as to increased
treatment costs [3]. International guidelines provide
recommendations for the initial evaluation and treat-
ment of LRTI and include advice about judicious an-
tibiotic therapy [4–7]. However, studies have shown a
wide variation of adherence to these guidelines in daily
practice [8].
A systematic review of studies of the improvement
of management of community-acquired pneumonia
(CAP) reported various strategies that can improve ad-
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herence to guidelines [9]. The most methodologically robust
study showed that the implementation of a critical-care path-
way is effective for reducing institutional resources, but it did
not assess the actual performance of processes of treatment and
showed no reduction in intensive care unit admission, read-
mission, or mortality rate [2]. Other studies have had a more
limited scope [10, 11] or did not control for secular trends [12,
13]. Thus, there is still a lack of research with regard to the
best approach to improve antibiotic use in hospitals.
Theories of effective change suggest that choosing potentially
effective intervention strategies is important and that interven-
tions should be tailored to the performance aspects most in
need of improvement; it is futile to invest in aspects for which
performance is already optimal. In addition, the choice of in-
tervention should be made on the basis of the assessment of
potential barriers to performance change for the target group
and context [14, 15]. To our knowledge, no specific studies to
improve in-hospital antibiotic treatment of patients with acute
exacerbations of chronic bronchitis (AECB) or chronic ob-
structive pulmonary disease have been published.
Therefore, we performed a cluster-randomized, controlled
trial at 6 hospitals; the aim was to improve the antibiotic treat-
ment of patients with CAP or AECB. We used an intervention
strategy that targeted the aspects most in need of improvement
(as indicated by the preintervention baseline performance) and
considered the barriers to appropriate antibiotic use.
PATIENTS AND METHODS
Study Design
We performed a multicenter, cluster-randomized trial to assess
the effectiveness of a multifaceted implementation strategy to
improve the quality of antibiotic use for LRTI. Six medium-
to-large hospitals in the southeast of The Netherlands took part
in this study. The trial was registered with ClinicalTrials.gov
(identifier, NCT00129883). The regional research ethics com-
mittee approved our study and waived the need for informed,
written consent from the patients. Measures were taken to pro-
tect patient privacy. Randomization took place at the hospital
level, but our intervention was delivered both at the hospital
level and at the professional level. To reduce chance imbalances,
we pair-matched the clusters for important variables, including
teaching status, hospital size, and mean outcomes for key in-
dicators in our baseline study. R.P.A., who was blinded to the
composition of the groups, flipped a coin to determine which
hospitals would be in the intervention and control groups.
Patients
We prospectively enrolled patients who were admitted to our
6 participating hospitals during 1 September 2002–1 March
2003 and 1 September 2004–1 March 2005. Eligible patients
with CAP met 3 of the following inclusion criteria: (1) age of
18 years, (2) evidence of an infiltrate on the chest radiograph
(as determined by the admitting professional or an onsite ra-
diologist) and 2 of 6 clinical criteria for CAP (cough, colored
sputum, temperature 138.5C, abnormal chest auscultation,
WBC count 1 cells/L or ! cells/L, or positive9 910 10 4 10
blood or pleural fluid culture result), and (3) a clinical diagnosis
of pneumonia that was established by the managing profes-
sional during hospitalization.
Eligible patients with AECB fulfilled the following inclusion
criteria: (1) age of 18 years; (2) recent increase in dyspnea,
sputum production, and/or change of aspect of sputum (at
least 2 of these 3 criteria); (3) a clinical diagnosis of AECB that
was established by the managing professional; and (4) the ab-
sence of a new radiographic infiltrate (as determined by the
admitting professional or an onsite radiologist).
We excluded the following patients: (1) patients who lived
in nursing homes, (2) patients who had underlying immu-
nodeficiency (HIV infection, neutropenia, receipt of treatment
with immunomodulating drugs, active hematological malig-
nancies, anatomical or functional asplenia, and hypogammag-
lobulinemia), (3) patients who were treated with antibiotics for
another culture-proven infection during the time of admission
to the hospital, (4) patients who had LRTI and were discharged
from the hospital during the preceding 30 days, (5) patients
who were transferred to another hospital or intensive care unit
or who died within 24 h of admission, and (6) patients who
had a very poor prognosis and who were admitted for palliative
care (i.e., they had a life expectancy of !2 weeks).
Variables
Process-of-care measures. Using a formal procedure, we se-
lected 15 indicators from key guideline recommendations (9
indicators for CAP and 6 for AECB) for the appropriate use
of antibiotics for LRTI on the basis of national and international
guidelines and a systematic review of the literature [16–19].
Five indicators were applicable to both AECB and CAP (tables
1 and 2). A sum score was calculated that determined the
percentage of patients who received all applicable quality in-
dicators (all-or-none measurement) [20]. Four additional in-
dicators were applicable only for CAP, and 2 were applicable
only for AECB (tables 3 and 4).
Patient outcome measures. We collected secondary out-
come measures, including duration of hospital stay, all-cause
in-hospital mortality, and intensive care unit admission for
hemodynamic compromise or respiratory failure.
Study Intervention
Analysis of barriers to implementation. Prior to our study,
we conducted a qualitative study to understand the barriers to
appropriate antibiotic use for patients with LRTI [21]. This
study suggested that different recommendations for the use of
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Table 3. Performance of additional quality indicators before and after intervention of treatment protocols for patients with community-
acquired pneumonia (by patient analysis).
Quality indicator
Intervention group Control group
ORa
(95% CI) P
Corrected ORb
(95% CI) P
Before
(n p 212)
After
(n p 276)
Change,
%
Before
(n p 166)
After
(n p 173)
Change,
%
Timely initiation of antibiotic therapy
(within 4 h after presentation) 80/145 (55.2) 105/167 (62.9) +7.7 66/97 (68) 33/64 (51.6) 16.4 2.49 (1.11–5.57) .0269 3.59 (1.02–12.6) .046
Stopping antibiotic therapy after 3
consecutive days of
defervescence 5/147 (3.4) 33/193 (17.1) +13.7 19/ 125(15.2) 9/120 (7.5) 7.7 13.86 (3.9–49.4) .0001 NAc
Obtaining 2 sets of blood samples
for culture 112/212 (52.8) 167/276 (60.5) +7.7 97/166 (58.4) 94/173 (54.3) 4.1 1.60 (0.83–3.07) .1545 1.65 (0.75–3.69) .20
Urine antigen testing for Legionella
species because of clinical
suspicion 11/14 (78.6) 20/24 (83.3) +4.7 12/16 (75.0) 12/13 (92.3) +17.3 0.34 (0.02–6.56) .4823 NAc
NOTE. Data are proportion of patients (%), unless otherwise indicated. NA, not applicable.
a ORs were adjusted for clustering of patients relative to professionals and hospitals in a multilevel analysis.
b ORs were corrected for potential patient, professional, and hospital confounding factors.
c No additional confounding factors tested [23].
Table 4. Performance of additional quality indicators before and after intervention of treatment protocols for patients with acute
exacerbation of chronic bronchitis (AECB) or chronic obstructive pulmonary disease (COPD; by patient analysis).
Quality indicators for AECB
Intervention group Control group
ORa (95% CI) P
Before
(n p 209)
After
(n p 193)
Change,
%
Before
(n p 232)
After
(n p 191)
Change,
%
Macrolide therapy not first
choice treatment for
bronchitis in exacerba-
tions of COPD 104/105 (99) 135/141 (95.7) 3.3 139/148 (93.9) 115/129 (89.1) 4.8 0.53 (0.06–5.10) .589
Optimal duration of antibi-
otic therapy from 5 to 7
days 24/93 (25.8) 47/127 (37.0) +11.2 73/141 (51.8) 51/119 (42.9) 8.9 2.22 (0.96–5.12) .062
NOTE. Data are proportion of patients (%), unless otherwise indicated.
a ORs were adjusted for clustering of patients relative to professionals and hospitals in a multilevel analysis.
an antibiotic have different barriers that must be overcome,
and different types of intervention are required. An example
that describes how the assessment of barriers leads to a “tar-
geted” intervention is provided in the Appendix. As such, we
designed interventions for each particular recommendation
(figure 1). Our intervention strategy comprised both fixed and
flexible phases.
Phase I. During the first, fixed phase of our intervention,
intervention hospitals (IHs) installed a local organizing com-
mittee. In each hospital, a clinical pharmacist, a medical mi-
crobiologist, a physician, a pulmonologist, and a quality-im-
provement officer participated. A key lecture was given in each
IH by a respected opinion leader during a kick-off meeting.
Feedback on indicator performance at the hospital level was
presented and provided in writing to all doctors treating hos-
pital LRTIs. Feedback reports included benchmarks at the hos-
pital level (best practice) and presented key issues for improve-
ment. Consensus “critical-care pathways” were distributed to
all doctors as a laminated, pocket card; desktop and personal
digital assistant versions were also distributed.
Phase II. During the flexible phase (phase II), the com-
ponents of intervention were adjusted to the needs and wishes
of every single IH. Local hospital baseline study results were
discussed during local organizing committee meetings. The in-
dicators that were most in need of improvement were given
priority in the intervention protocol. The elements for inter-
vention were selected on the basis of analysis of the barriers
that were specific to each key guideline recommendation. These
interventions were implemented in 3 modules, including ini-
tiation of therapy, change of therapy, and diagnostic procedures
(figure 1). Local processes of treatment were analyzed, and work
processes were redesigned. Our external quality facilitator ini-
tiated and coordinated this intervention.
Data Collection
All data were collected by concurrent chart review; trained
research assistants made twice-weekly reviews of the charts of
all patients who were admitted to the internal and respiratory
medicine wards. Patient characteristics included demographic
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Figure 1. Flowchart of hospitals and patients
data, comorbidity data, findings from a physical examination
that was performed during admission, and initial laboratory
and radiology results (tables 5 and 6). Data collection was val-
idated at regular intervals; 2 independent researchers performed
double-chart reviews for 10% of the patients. These researchers
agreed on indicator level, which was corrected for chance and
expressed in k coefficients, with a range of 0.7–1 (good to very
good).
Care-provider characteristics were collected from question-
naires that were completed by all specialists at our study hos-
pitals. Hospital characteristics were obtained from a national
survey (table 7) [22].
Statistical Analysis
Descriptive statistics included frequencies, percentages, means,
medians, and SDs. Hospital, professional, and patient charac-
teristics of study hospitals were compared with Student’s t test
and a nonparametric test (Mann-Whitney U test) for contin-
uous variables and a x2 analysis for proportions. wasP ! .05
considered to be statistically significant. We performed a mul-
tilevel logistic analysis to assess effectiveness, adjusting for clus-
tering of patients and professionals in hospitals. We calculated
the intraclass correlation coefficients to rate the degree of clus-
tering. We constructed the generalized estimating equation
models with a Glimmix procedure, using SAS statistical soft-
ware, version 8.2 for Windows (SAS Institute). For each in-
dicator outcome, the basic model included effects on the in-
tervention group versus the control group and on the timing
of measurement (preintervention vs. postintervention). The
model also included the interaction between these 2 variables.
For each specific indicator, results were adjusted for patient,
professional, and hospital factors that independently predicted
indicator performance [23]. The adjusted estimates and their
associated SEs were converted to ORs with 95% CIs.
RESULTS
Study Population
At baseline, our intervention group consisted of 470 patients
(238 patients with CAP and 232 patients with AECB), and our
control group consisted of 405 patients (194 patients with CAP
and 211 patients with AECB). The postintervention groups
included 587 intervention patients and 444 control patients
(figure 2). Exclusion rates varied from 10.4% to 17.8%, and
exclusions were mainly attributable to the recent discharge
(within 30 days) of patients with LRTI (tables 5 and 6).
No clinically relevant differences were detected for charac-
teristics of hospitals and professionals between our IHs and
CHs at baseline (table 7). Fewer patients with chronic obstruc-
tive pulmonary disease were included in our CAP control group
at baseline than in the intervention group (table 5). This was
because the patient inclusion rate was higher in the general
internal medicine wards than in the respiratory units of our
CHs at baseline. This may have led to an uneven distribution
of patients with chronic heart failure (46.2% vs. 27.7%; P !
) and of patients with 11 comorbidity (44.8% vs. 33.7%;.01
).Pp .03
Effects
Table 1 shows the pre- and postintervention performance of 5
quality indicators and a sum score. Table 2 shows the outcomes
per hospital. Performance improved statistically significantly
for 2 of 5 indicators in our IHs, compared with the CHs.
Guideline adherence for empirical antibiotic therapy.
The rate of adherence to guidelines for empirical therapy in-
creased from 50.3% to 64.3% in the IHs (OR, 2.63; 95% CI,
1.57–4.42). Improvement was equally distributed among the 3
IHs (increases of 12.4%, 15.6%, and 14.0%). However, in hos-
pital 1, this was predominantly because of an improvement in
the administration of antibiotics at the correct indication for
AECB (from 29.1% to 51.5%), rather than because of the pre-
scription of antibiotics according to the CAP guideline (from
56.3% to 63.9%). In hospital 2, empirical prescription for both
AECB and CAP improved, and in hospital 3, all improvement
was because of better adherence to recommendations for the
treatment of CAP (from 39.5% to 53.3%).
Adapting the dose and dose interval in the presence of de-
creased renal function. At baseline, there was a significant
difference between adherence to the adaptation of the dose and
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Table 5. Patient characteristics before and after intervention of treatment protocols for patients with community-acquired pneumonia.
Characteristic
Baseline cohort Postintervention cohort
Intervention
(n p 238)
Control
(n p 194) P
Intervention
(n p 318)
Control
(n p 207) P
Evaluable patients 212 166 … 276 173 …
Male sex 124 (58.5) 93 (56) .63a 174 (63) 106 (61.3) .71a
Age, mean years  SD 69.6  16.2 70.8  14.6 .47b 68.7  16.2 71.8  16.4 .05b
PSI score 13 99 (46.7) 78 (47) .96a 130 (47.4) 84 (48.8) .78a
Comorbidity scorec 11 95 (44.8) 56 (33.7) .03a 94 (34.1) 75 (43.1) .05a
COPD 109 (51.4) 62 (37.3) .01a 129 (46.7) 91 (52.6) .23a
Chronic heart failure 98 (46.2) 46 (27.7) !.01a 84 (30.4) 36 (20.8) .025a
Confusion during presentation 17 (17.7) 15 (25.4) .25a 21 (12.8) 28 (17.4) .25a
Oxygen saturation, mean %  SD 93  4.5 91.9  4.9 .06b 93.3  4.8 92.3  4.5 .05b
Temperature, mean C  SD 38.1  1.1 37.9  1.1 .01b 38.2  1.0 38.0  1.1 .2b
Pulse, mean beats/min  SD 98.3  19.6 94.8  21.8 .12b 98.1  19.4 96.5  20.8 .43b
Sodium level, mean mmol/L  SD 137.3  4.1 135.5  4.9 .01b 136.6  4.4 136.2  4.1 .43b
Antibiotic therapy within 30 days 70 (33.0) 49 (29.5) .92a 83 (30.0) 58 (33.5) .32a
Admission to respiratory unit 181 (87.4) 99 (59.6) !.01a 229 (83) 158 (91.3) .012a
Hospital mortality 13 (6.1) 15 (9.0) .29a 20 (7.2) 15 (8.7) .58a
ICU admission 5 (2.4) 7 (4.2) .31a 6 (2.2) 2 (1.2) .43a
Duration of stay, median days 10.0 12.0 .23b 8.0 10.0 .47b
NOTE. Data are no. (%) of patients, unless otherwise indicated. COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; PSI, pneumonia
severity index.
a Determined by x2 test.
b Determined by Student’s t test or Mann-Whitney U test.
c Sum score of 8 items, including malignancy, liver disease, chronic heart failure, stroke, renal failure, diabetes, alcohol abuse, and chronic lung disease.
dose interval in the presence of decreased renal function be-
tween the IHs and the CHs (79.4% vs. 95.8%). The rate of
adherence to this indicator increased in our IHs (from 79.4%
to 95.1%), and a ceiling effect occurred in the CHs (the rate
decreased slightly from 95.8% to 92.4%).
Switch therapy. The switch from intravenous to oral ther-
apy improved in our IHs (from 74% to 83.6%) and even more
in our CHs (from 53.3% to 71.9%). The increase was most
prominent in one of the control hospitals; hospital 4 had an
increase of 31.2% (from 21.9% to 53.1%).
Streamlining therapy. The change from broad-spectrum
provisional therapy to pathogen-directed therapy for LRTIs
showed an overall 5.7% improvement in our IHs. In the CHs,
performance decreased (from 66.2% to 57.1%). Streamlining
therapy was only possible for a small number of patients. There
were 111 such patients (26%) in the intervention group at
baseline, and there were only 71 eligible patients (19.7%) in
the control group. The increase in adherence for this indicator
was not statistically significant (OR, 1.88; 95% CI, 0.32–11.03;
).Pp .46
Performance of diagnostic procedures: sputum sample for
Gram staining and culture. Fewer sputum samples were ob-
tained both from the intervention group (from 55.8% to
53.1%) and the control group (from 49.6% to 42.7%). Overall,
there was a 7% increase of patients who received all recom-
mended processes of treatment in the intervention group (from
22.1% to 29.1%; OR, 1.77; 95% CI, 0.94–3.34; ).Pp .079
Additional quality indicators for CAP and AECB. For the
remaining 4 quality indicators for CAP, a moderately positive
effect of the intervention was detected (table 3). Timeliness of
antibiotic administration increased significantly (from 55.2%
to 62.9%; ). For AECB, “not prescribing macrolides”Pp .03
was already optimal at baseline. Optimal duration of admin-
istering antibiotics for AECB increased 11.2% (from 25.8% to
37%) in our IHs (table 4).
DISCUSSION
Considering the barriers to guidelines on judicious use of an-
tibiotics during the conception, dissemination and implemen-
tation of a multifaceted intervention strategy and tailoring this
strategy to the aspects that were most in need of improvement
had an impact on the quality of antibiotic treatment of patients
hospitalized with LRTI.
We found that, for some quality indicators, a significant and
clinically relevant improvement could be achieved. For other
indicators, such as streamlining therapy, there was no statis-
tically significant improvement, but there was a trend towards
better performance in the intervention group. Switch therapy
also greatly improved in control hospitals. This increase was
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Table 6. Characteristics of patients with acute exacerbation of chronic bronchitis or chronic obstructive pulmonary disease before
and after intervention of treatment protocols.
Characteristic
Baseline cohort Postintervention cohort
Intervention
(n p232)
Control
(n p211) P
Intervention
(n p269)
Control
(n p 237) P
Evaluable patients 209 193 … 232 191 …
Male sex 105 (50.5) 102 (52.8) .64a 121 (52.2) 110 (57.6) .26a
Age, mean years  SD 69.9  11.2 67.8  13.6 .08b 68.9  11.3 68.5  10.8 .70b
FEV1, mean %  SD
c 47.6  16.0 48.1  16.5 .81b 46.7  16.9 47.1  18.1 .852b
Oxygen saturation, mean %  SD 93.7  4.9 91.5  5.5 !.05b 93.2  4.7 92.7  5.4 .34b
Temperature, mean C  SD 37.3  0.7 37.2  0.7 .07b 37.4  0.8 37.1  0.8 !.05b
Pulse, mean beats/min  SD 91.9  19.9 94.6  21.2 .19b 95.4  18 94.9  18 .78b
Sodium level, mean mmol/L  SD 138.5  3.8 137.9  3.5 .15b 139.2  3.9 138.8  4.1 .44b
Antibiotic therapy within 30 days 51 (24.4) 65 (30.8) .45a 82 (35.3) 55 (28.8) .22a
Admission to respiratory unit 189 (90.4) 184 (95.3) .06a 229 (98.7) 188 (98.4) .81a
Hospital mortality 19 (9.1) 12 (6.2) .28a 10 (4.3) 5 (2.6) .35a
ICU admission 1 (0.5) 3 (1.6) .19a 5 (2.2) 0 (0.0) .04a
Duration of stay, median days 12.1 12.3 .82b 11.5 11.4 .89
NOTE. Data are no. (%) of patients, unless otherwise indicated. FEV1, forced expiratory volume in 1 s; ICU, intensive care unit.
a Determined using x2 test.
b Determined using Student’s t test or Mann-Whitney U test.
c Percentage of predicted value.
Figure 2. Flow diagram of intervention (Adherence to Guidelines for Antibiotic Use in Respiratory Tract Infections Trial; only key indicators for lower
respiratory tract infection are depicted). AECB, acute exacerbations of chronic bronchitis or chronic obstructive pulmonary disease; CAP, community-
acquired pneumonia.
most obvious in one hospital, where process evaluation taught
us that 2 young pulmonologists implemented a local switch
protocol. In 2004, there was a key publication about the safety
of intravenous-to-oral switch in the Dutch Medical Journal [24],
and it is likely that a national trend in promoting switches in
therapy was responsible for the effect that was observed in both
the IHs and CHs. An overall decrease of performance was noted
for “obtaining a sputum sample,” despite our intervention. This
may reflect a trend in the recent literature to question the need
for diagnostic procedures, such as blood and sputum cultures,
for every patient with LRTI [25, 26]. Secular trends (such as
those mentioned here) can affect any study design, but one of
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Table 7. Baseline characteristics of hospitals and professionals.
Characteristic
Intervention
hospitals
Control
hospitals P
Hospitala
Mean no. of beds  SD 522  54 566  80 NA
No. of teaching hospitals 2 2b NA
No. of antibiotic committees 1 2 NA
No. of hospitals that use local antibiotic guidelines 3 3 NA
No. of hospitals that use of national guidelines to compose local policies 1 1 NA
No. of hospitals that use routine feedback on pathogen-directed therapy 1 1 NA
No. of hospitals that had a quality improvement project during the prior 5 years 2 3 NA
No. of hospitals that had a pharmacist present at ward rounds to discuss antibiotic prescription 1 2 NA
Professionalsc
Age, mean years  SD 48.1  6.6 49.1  9.2 .69d
Proportion of men (%) 19/24 (79.2) 23/29 (79.3) .99e
Mean no. of years in practice  SD 20.4  7.0 21.7  9.9 .62d
Proportion of pulmonologists (%) 13/25 (52) 15/29 (51.7) .98e
Clinical experience, proportion treating 125 patients with CAP per year (%) 16/23 (69.6) 22/28 (78.6) .78e
Member of local antibiotic committee, ratio (%) 1/23 (4.3) 4/28 (14.3) .24e
Special task in guideline composition, proportion (%) 6/23 (26.1) 10/27 (37.0) .41e
NOTE. CAP, community-acquired pneumonia; NA, not applicable.
a Data are for 3 hospitals in both the intervention and the control groups.
b Value during postintervention; hospital 5 became a teaching hospital during the intervention period.
c Twenty-five professionals in the hospital group and 29 in the control group.
d Determined using Student’s t test.
e Determined using x2 test.
the key advantages of our clustered, controlled design is that
it prevents contamination between the intervention and control
groups; therefore; changes in the control group can be more
reliably attributed to external secular trends [27].
Our results confirm those of other studies that have evaluated
the effectiveness of quality improvement strategies for the treat-
ment of LRTI [28–30]. Our results agree with a study by Halm
et al. [28] that showed the partial and limited impact of a quite
comparable, multifactorial intervention strategy. However, the
study had no control group. In a randomized, controlled study,
Yealy et al. [31] investigated the effects of increasing the in-
tensity of guideline-implementation strategies on recom-
mended processes of treatment; the implementation strategy
with the highest intensity most closely resembles our strategy.
The highest intensity strategy showed a benefit for all of the
recommended processes of treatment that was much larger
(60.9%) than that of our strategy, in which overall performance
in the intervention group increased from 22.1% to 29.1%. Un-
fortunately, in the study by Yealy et al. [31], no preintervention
data were collected, and therefore, possibly large institutional
differences at baseline were not taken into account.
In previous studies, quality indicators were based on data
elements that were easy to collect. This may have increased the
feasibility of the inclusion of large numbers of patients; how-
ever, it may have also compromised the exactness of “what
really happened at the bedside of the patient.” For example,
the median number of days of intravenous therapy is often
used as an easy-to-measure outcome for a timely switch from
intravenous to oral therapy. However, measuring professional
practice “close to the patient” by studying sequential antibiotic
prescriptions in detail for every patient (thus including correct
decisions not to switch from intravenous to oral therapy—e.g.,
for patients with septicemia or lung empyema) more exactly
described the quality of actual treatment provided. This allowed
us to further clarify which aspect of the process underlying the
indicator failed and, thus, helped us to better target our inter-
vention strategy.
Nonetheless, our study has some limitations. First, the absence
of systematic data sources at Dutch hospitals and the use of
elaborate, time-consuming data collection methods limited our
number of study hospitals. Thus, it was difficult to enroll the
required number of patients to participate in some important
processes of treatment for both CAP and AECB. Second, our
study was only designed to assess changes in performance on
the basis of process-of-care indicators. Although we included
patient-outcome parameters in our data collection, we cannot
draw any conclusions from the results of these parameters, other
than that our intervention was probably safe. However, some
process indicators have proven to be firmly associated with im-
proved survival and may thus be regarded as surrogates for pa-
tient outcome [32]. Third, although our intervention showed
improvement in processes of treatment, it remains unclear which
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specific parts of our complex, multifaceted intervention contrib-
uted to the limited success. Again, with the limited number of
hospitals, a 3-arm design was not feasible. We assumed, how-
ever, that such combined interventions are needed to achieve
changes in complex problems, such as the inappropriate use of
antibiotics. Meticulous process evaluation in all of the IHs en-
abled us to detect some successful aspects of the intervention.
Finally, our study design does not provide any information about
the sustainability of the performance improvements. No remea-
surement was performed during the year following the inter-
vention. Future studies should focus on this important aspect of
implementation research.
Although our intervention was shown to be successful in a
randomized, controlled setting, the enormous efforts to collect
adequate data illustrates the limited feasibility of this type of
study and makes this study quite unique. Performance of high-
quality, cluster-randomized, controlled trials with different
arms of intervention and the prospective collection of data (that
are measured close to the patient) regarding aspects of treat-
ment require large patient cohorts and, thus, appropriate fund-
ing [33, 34]. Other designs, like time-series intervention anal-
ysis, may prove to be more cost-effective for achieving a
comparable level of evidence [27, 35].
In conclusion, the implication of our work is that tailoring
interventions can improve the quality of antibiotic use for pa-
tients hospitalized with LRTI. We therefore recommend that—
however time-consuming this may seem—possible areas in
need of improvement and barriers to change be extensively
explored before clinical guidelines or changes in patient treat-
ment are implemented.
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APPENDIX
FROM BARRIERS TO AN INTERVENTION
STRATEGY
For the recommendation “starting empirical therapy at a cor-
rect indication and according to national guidelines,” the fol-
lowing different barriers that need to be overcome were re-
ported: (1) doctors’ disagreements with current national
guideline recommendations (these were because of a reported
lack of evidence justifying the recommendations and a lack of
confidence in the guideline developers), and (2) peer pressure
among doctors about empirical antibiotic choice (notably, at
end-of-shift meetings).
To overcome these barriers, representatives of all the relevant
clinical specialties should participate in developing a local con-
sensus guideline on the basis of the available evidence, which
should lead to clear and unequivocal critical-care pathways for
both CAP and AECB. Journal clubs should be organized to
discuss controversies in the literature about the preferred an-
tibiotic management of CAP and the indications of antibiotic
use for AECB. A 1-h feedback and tutorial session should be
organized for the colleagues, in which peers compare their
personal performances with respect to guideline adherence and
discuss differences.
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